Leukemia patients remain in remission more than two years after engineered T cell therapy
Monday, December 10, 2012 - 08:30
in Health & Medicine
Nine of 12 leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy.